| Description |
Recombinant HEK 293 cell line expressing the human ERG (ether-a-go-go related gene) potassium channel (NM_000238).
|
| |
Biochemical validation |
Immunofluorescence of hERG HEK 293 recombinant cells or wild type HEK 293 cells with anti-hERG antibody (red). Nucleus staining is performed with Hoechst (blue). |
 |
| |
| Biochemical validation |
Western blot analysis of recombinant or wild type HEK 293 total cell extracts with anti-hERG antibody. |
 |
| |
Patch clamp
validation |
Solutions:
- Extracellular solution: 118 mM NaCl, 5.6 mM KCl, 2.4 mM CaCl2, 1.2 mM MgCl2, 10 mM
HEPES, 11 mM glucose, pH 7.2
- Intracellular pipet solution: 30 mM KCl, 110 mM K-aspartate, 0.1 mM CaCl2, 1 mM MgCl2,
1 mM EGTA, 10 mM HEPES, pH=7.2
- Terfenadine: SIGMA T9652. |
Recording procedure:

|
| Configuration: whole-cell. |
Reference: Wang J et al. Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H256-67. |
| |
Patch clamp
validation |
Currents recorded from hERG HEK 293 recombinant cell line: |
 |
| |
|
| |
I-V curves - Terfenadine (100 nM): |
 |
| |
|
| |
Maximal current inhibition of hERG with 100 nM terfenadine: |
 |
| |
|
| |
Current stability over continuous culture: |
| |
The hERG HEK 293 recombinant cell line was propagated over 5 months under the recommended growth conditions. There was no significant variation in expression of the hERG current over this period. |
| |
|
| |
|
| |
|
To know more about QT Interval Prolongation & guideline: ICH Guideline, S7A & S7B |